Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320149 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 968
- Enrollment target
NCT02320149 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 968 participants.
The verdict
NCT02320149, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 968 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Interventions
- DRUG Placebo
- DRUG Sarecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 968 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320149
The ClinicalTrials.gov registry entry for NCT02320149 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 968 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02320149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320149 about?
NCT02320149 is a clinical study titled "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne". To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
What is the current status of trial NCT02320149?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 968 participants. The study started on 2014-12-18. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02320149?
The interventions under investigation include: Placebo (DRUG), Sarecycline (DRUG).
Who is sponsoring clinical trial NCT02320149?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.